Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Adjuvant Therapies for Infratentorial Hemangioblastomas in Children

This page was last updated on January 25th, 2023

Adjuvant therapy is not required after complete resection of a hemangioblastoma. It can be considered to manage lesions not amenable to surgical treatment.


  • Conventional therapy: Conventional radiotherapy may be considered for the management of surgically inaccessible and/or multiple hemangioblastomas in older children or adolescents. The goal is to avoid multiple operations in cases of hemangioblastomatosis or to delay surgery on a tumor with progressive growth.
  • Stereotactic radiosurgery: Stereotactic radiosurgery may be considered for appropriate targets at doses of 20–24 Gy through a frame-based linear accelerator, Gamma-knife, or Cyberknife (2, 4, 35). Radiosurgery is indicated for hemangioblastomas with a mean volume of 1–2 cm3 (range: 0.01–65 cm3).


  • Antiangiogenic therapy: VEGF inhibition can be used to delay the growth of progressing and inoperable hemangioblastomas (32). Otherwise, the low proliferative index of these tumors renders them resistant to chemotherapy.

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.